Navigation Links
Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests
Date:10/25/2007

LOD, Israel, October 25 /PRNewswire/ -- Glycominds Ltd., a bio-diagnostics company specializing in glycan biomarkers for diagnosis and disease management of autoimmune diseases and cancer, announced today entering into a research agreement with Fox Chase Cancer Center (FCCC), an NCI designated cancer center to develop a new diagnostics blood test for breast cancer.

"We are very pleased to work with FCCC on this project," stated Dr. Nir Dotan, Glycominds' co-founder, CTO and VP R&D. "Glycominds' anti-glycan antibodies biomarkers approach together with the FCCC excellent patient records, samples and clinical know-how give this project a high basis for success."

"Glycominds' glycan biomarker technology stands out as innovative and unique. We hope that just as Glycominds was able to successfully develop new diagnostic and prognostic biomarkers for Autoimmune disorders, we will be able to identify glycans that can be useful in the early detection of cancer," stated Dr. Andrew K. Godwin, FCCC's Director of the Clinical Molecular Genetics Laboratory and the Biosample Repository . "I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer and improve the health and quality of life for millions of women."

About Glycominds Ltd.

Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008. The Company's gMS(TM) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(TM) PRO, a prognostic test for MS activity, are also expected to enter the market in 2008. Glycominds' other pipeline products include blood tests for the prediction of recurrent pregnancy loss based on hyper-coagulation caused by antiphoshpholipids syndrome (APS), and first-in-class screening tests for breast and colorectal cancers. http://www.glycominds.com

For more information, please contact:

Glycominds, Ltd.

Dr. Avinoam Dukler

Chief Executive Officer

dukler@glycominds.com

The Ruth Group

Sara Ephraim (investors)

Phone: +1-646-536-7002

sephraim@theruthgroup.com

Janine McCargo (media)

Phone: +1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Glycominds Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Purchase of Madison broadband network may bring improved service
2. Wisconsin fares slightly better in venture capital chase
3. Metavante completes purchase of check processing firm
4. Logicalis purchases Solution Technology for $90M
5. Merge eFilm announces stock repurchase plan
6. Wisconsin based Graphics Distribution, Inc. purchased by Florida company
7. GE Medicals Acquisitions May Prompt More Purchases
8. Green Bay Software Company Purchased by GE
9. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
10. Cancer siRNA Oligo Set Version 1.0
11. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
Breaking Biology News(10 mins):